TiumBio Co., Ltd. (KOSDAQ: 321550)

Market Cap	104.90B
Revenue (ttm)	7.67B
Net Income (ttm)	-20.35B
Shares Out	26.39M
EPS (ttm)	-799.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,438
Average Volume	42,022
Open	4,000.00
Previous Close	4,000.00
Day's Range	3,930.00 - 4,080.00
52-Week Range	3,605.00 - 9,050.00
Beta	0.78
RSI	36.45
Earnings Date	Mar 21, 2025

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. TiumBio Co., Ltd. was founded in 2016 and is based in Seongnam-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 42
• Stock Exchange: KOSDAQ
• Ticker Symbol: 321550

Financial Performance

In 2023, TiumBio's revenue was 4.90 billion, a decrease of -46.27% compared to the previous year's 9.12 billion. Losses were -17.91 billion, -40.00% less than in 2022.